Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of TRS003 vs Bevacizumab in Healthy Males
NCT03882424Phase 1Completed
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RPH-001 in metastatic colorectal cancer (mCRC), Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), glioblastoma (GBM) and 5 more (3 arms), sponsored by Zhejiang Teruisi Pharmaceutical Inc. Primary endpoint: Area Under the Serum Concentration Versus Time Curve from Time 0 to Infinity at 2016 hours. Started Jun 2018; status: completed.
02
Drugs
RPH-001
03
Conditions
metastatic colorectal cancer (mCRC)Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)glioblastoma (GBM)metastatic renal cell carcinoma (mRCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03882424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882424.